Abbvie Inc. (ABBV)
The company now
Abbvie is classed as a product business in the Pharmaceutical Preparations sector. Abbvie tags no split of its revenue by line in the annual report on file, so growth by line cannot be read. 31
From the record in brief, written by the desk, an AI model, from the company's record on Oct 22, 2026. Nothing here is advice.
Where the revenue comes from
No split of its revenue is on file yet.
The desk's written account of this company, its Past, Present and Future, is not on file yet.
How the company works
The desk has not read this company's annual report yet.
The record in brief
five sections from the recordBy the desk, an AI model (Claude Haiku 4.5), written from the company's record on Oct 22, 2026; nothing here is advice. Every sentence rests on the numbered source beside it, and a sentence the record did not support was cut before the report was kept.
A newer quarterly report (Form 10-Q, filed 2026-11-03) and current report (Form 8-K, filed 2026-11-02) is on file; this report was written before it, and the desk writes it again on request.
Past
Abbvie's revenue grew from $26 billion in fiscal 2016 to $61 billion in fiscal 2025, up 10.1% a year, rising in 8 of 9 years with a deepest fall of 6% from fiscal 2022 to fiscal 2023; net income was positive in all 10 years on file. Over the three fiscal years to 2025, the diluted share count shrank about 0.1% a year, and dividends and buybacks returned about 62% of operating cash flow. Dividends declared per share rose from $2.35 in fiscal 2016 to $6.65 in fiscal 2025. The grade reads past 8.0 of 10. 123
Present
In the fiscal year ended 2025-12-31, Abbvie reported revenue of $61 billion and profit of $4.2 billion. Shareholders' equity was below zero, so return on equity is not read; gross profitability was about 32 cents per dollar of everything the company owns; leverage was about 102 cents per dollar of assets; and the share count was unchanged over the year. Revenue of $61 billion ranks in the top 2% by size among 315 graded names in its family; a net margin of 6.8% ranks in the top 19%; revenue growth of 1.8% a year over the last three filed years ranks in the bottom 40%. The chief executive is Michael Robert A. , filing under that title since 2025-02-18, 1.7 years; the 21 officers and directors filing in the last fifteen months have been on the record a median of 8.5 years. The grade reads present 6.1 of 10. 31
Future
A quarterly report for the quarter ending 2026-09-30 is due by 2026-11-09. An annual report for the fiscal year ending 2026-12-31 is due by 2027-03-01. Cash of $5.2 billion against debt of $59 billion leaves negative 40.1% of assets as net cash, in the bottom 3% of its family; cash from operations less capital spending is 29.1% of revenue, in the top 7%; gross margin is 70.2%, in the bottom 49%; research spending is 14.9% of revenue, in the bottom 19%. Revenue grew 1.8% a year over the last three filed years against 10.1% over all 10, slowing; the newest year grew 8.6%; research spending grew 11.8% a year; capital spending grew 20.4% a year. Revenue of $61 billion in fiscal 2025 came in 10.2% above the $55 billion the prior three years' pace pointed to; net income of $4.2 billion came against a prior three-year average of $6.9 billion; net margin of 6.8% came against 12.2% before. The grade reads future 4.6 of 10. 413
How the company operates
Abbvie is classed as a product business in the Pharmaceutical Preparations sector. Abbvie tags no split of its revenue by line in the annual report on file, so growth by line cannot be read. 31
New moves
On 2026-10-15, Abbvie filed a Form 8-K reporting an officer or director change. On 2026-10-05, Abbvie filed a Form 8-K releasing results. On 2026-08-06, Abbvie filed a Form 424B5 shelf offering, securities sold off a shelf. On 2026-08-04, Abbvie filed a Form 424B5 shelf offering, securities sold off a shelf. On 2026-10-15, a Form 8-K was filed. 45
Sources
a number beside a sentence opens its entry in its own document's listThe record in brief 5 sources · written Oct 22, 2026
- ABBV: the nine metricsthis site's record
show the quoted words
Track record (past, graded 7.5 of 10, weighs 45% of the past): Abbvie Inc.'s 10 filed years say what it did: revenue went from $26 billion in fiscal 2016 to $61 billion in fiscal 2025, up 10.1% a year; it rose in 8 of 9 years; the deepest fall was 6% from fiscal 2022 to fiscal 2023; net income was positive in 10 of 10 of those years (its annual reports).
Shareholder treatment (past, graded 8.9 of 10, weighs 22% of the past): Over the 3 fiscal years to 2025-12-31, Abbvie Inc.'s diluted share count shrank about 0.1% a year, and dividends and buybacks returned about 62% of its operating cash flow over 3 years (its filed statements).
Financial health (present, graded 5.4 of 10, weighs 45% of the present): Return on equity: in the fiscal year ended 2025-12-31, Abbvie Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 32 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 102 cents per dollar of as
Industry position (present, graded 7.3 of 10, weighs 33% of the present): Abbvie Inc.'s standing among 315 graded names in its industry family: revenue of $61 billion in fiscal 2025 ranks in the top 2% by size; a net margin of 6.8% ranks in the top 19%; revenue growth of 1.8% a year over the last 3 filed years ranks in the bottom 40% (its annual reports).
Leadership (present, graded 5.9 of 10, weighs 22% of the present): Abbvie Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Michael, Robert A. (CHAIRMAN OF THE BOARD AND CEO, as filed), filing under that title since 2025-02-18, 1.7 years (bottom 21% of its family); the 21 officers and directors filing in the last fifteen months have been on
Room to expand (future, graded 4.1 of 10, weighs 45% of the future): Abbvie Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $5.2 billion against debt of $59 billion leaves -40.1% of its assets as net cash, bottom 3% of its family; cash from operations less capital spending is 29.1% of revenue (top 7%); a gross margin of 70.2% (bottom 49%); research spending of 14.9% of
Growth drivers (future, graded 5.7 of 10, weighs 33% of the future): Abbvie Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 1.8% a year over the last three filed years against 10.1% over all 10, slowing (bottom 38% of its family); the newest year grew 8.6% (top 50%); research spending grew 11.8% a year (top 36%); capital spending grew 20.4% a year (top 24%) (its annual rep
Expectations vs reality (future, graded 4.2 of 10, weighs 22% of the future): Abbvie Inc.'s newest year against its own record: revenue of $61 billion in fiscal 2025 came in 10.2% above the $55 billion its prior three years' pace pointed to (top 34% of its family); net income of $4.2 billion against a prior three-year average of $6.9 billion (bottom 28%); a net margin of 6.8% against 12.2% before
Abbvie Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
- ABBV: the statements' history (names, splits, dividends per share)a filing
show the quoted words
Dividends declared per share (USD per share, what it declared for each share in the period), by fiscal year: FY2025 6.65; FY2024 6.29; FY2023 5.99; FY2022 5.71; FY2021 5.31; FY2020 4.84; FY2019 4.39; FY2018 3.95; FY2017 2.63; FY2016 2.35.
- ABBV: the company filethis site's record
show the quoted words
Headline grade 6.3 of 10; the arc reads past 8.0, present 6.1, future 4.6; 9 of 9 metrics read as filed.
In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $61 billion and a profit of $4.2 billion (its filed statements).
Product business (prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it). Sector: Pharmaceutical Preparations (SIC 2834).
- ABBV: the filing record, ten yearsa filing
show the quoted words
Deadline ahead: Quarterly report (Form 10-Q) for the quarter ending 2026-09-30 is due by 2026-11-09; large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
Deadline ahead: Annual report (Form 10-K) for the fiscal year ending 2026-12-31 is due by 2027-03-01; large accelerated filers have 60 days after the fiscal year ends.
2026-10-15: Form 8-K, Current report (Officer or director change, item 5.02), for the period ended 2026-10-14.
Document: https://www.sec.gov/Archives/edgar/data/1551152/000110465926116227 2026-10-05: Form 8-K, Current report (Results released, item 2.02).
Document: https://www.sec.gov/Archives/edgar/data/1551152/000110465926098367 2026-08-06: Form 424B5, Shelf offering. The filing record and the share count: securities sold off a shelf.
Document: https://www.sec.gov/Archives/edgar/data/1551152/000110465926090611 2026-08-04: Form 424B5, Shelf offering. The filing record and the share count: securities sold off a shelf.
- ABBV: the alerts of the last thirty days (headlines only; the desk has not read the articles)this site's record
show the quoted words
2026-10-15, SEC EDGAR, current 8-K filings: "Abbvie Inc. filed a Form 8-K"